NeuShen Therapeutics, a Shanghai-and-Boston biotech led by a transpacific executive team, raised more than $80 million in a disclosed Series B to advance three clinical-stage brain-health drug programs. The company positioned the funding to support continued development and progression across its pipeline. The financing underscores ongoing investor interest in CNS therapeutics even as the sector demands differentiation on mechanism, trial execution, and eventual regulatory path. With multiple programs at or near clinical readouts, NeuShen’s capital plan is geared toward maintaining momentum rather than extending only discovery timelines. For the biotech industry, the deal is another example of cross-border capital allocation into late-stage CNS assets, where scientific risk is high but clinical-stage milestones can sharpen valuation. It also adds to the roster of companies betting on diversified CNS indications rather than single-program concentration.